Company profile for Trevi Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are developing nalbuphine ER to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems. Nalbuphine ER is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting. ...
We are developing nalbuphine ER to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems. Nalbuphine ER is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting. Our novel oral formulation is unlocking new market opportunities and the potential to significantly improve the quality of life of patients who currently have few treatment options.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
195 Church Street, 14th Floor New Haven, CT 06510
Telephone
Telephone
(203) 304-2499
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Trevi Pharma Names David Hastings CFO
Trevi Pharma Names David Hastings CFO

04 Dec 2025

// PR NEWSWIRE

https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-appointment-of-david-hastings-as-chief-financial-officer-302632615.html

PR NEWSWIRE
04 Dec 2025

https://www.prnewswire.com/news-releases/trevi-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-updates-302614805.html

PR NEWSWIRE
13 Nov 2025

https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-third-quarter-2025-financial-results-and-provide-a-corporate-update-on-november-13-2025-302607029.html

PR NEWSWIRE
06 Nov 2025

https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-stifel-2025-healthcare-conference-302602653.html

PR NEWSWIRE
04 Nov 2025

https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-oral-presentation-and-abstracts-at-chest-2025-annual-meeting-302577932.html

PR NEWSWIRE
08 Oct 2025

https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-two-posters-from-the-phase-2a-river-trial-data-will-be-featured-at-the-european-respiratory-society-ers-congress-2025-302559765.html

PR NEWSWIRE
18 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty